Dapa has been applied globally for treating type 2 diabetes and the positive efficacy of Dapa in cardiovascular disease recommends the SGLT2 inhibitors in HFrEF treatment in the international heart failure guidelines [25, 26]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.